Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 18/20 | 1.00 |
| ▸ | PDE2A | O00408 | 1/20 | 1.00 |
| ▸ | SLC28A2 | O43868 | 1/20 | 1.00 |
| ▸ | PDE5A | O76074 | 1/20 | 1.00 |
| ▸ | PDE6A | P16499 | 1/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | PDE7A | Q13946 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.38 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26838918 | 0.92 | PDE10A (0.85) | PDE10APDE2ASLC28A2PDE5APDE6A | |
| SCHEMBL415202 | 0.90 | PDE10A (1.00) | PDE10APDE2ASLC28A2PDE5APDE6A | |
| SCHEMBL415134 | 0.85 | PDE10A (1.00) | PDE10APDE2ASLC28A2PDE5APDE6A | |
| SCHEMBL444730 | 0.80 | PDE10A (1.00) | PDE10APDE2ASLC28A2PDE5APDE6A | |
| SCHEMBL7884906 | 0.79 | PDE10A (0.76) | PDE10APDE2ASLC28A2PDE5APDE6A | |
| SCHEMBL442733 | 0.77 | PDE10A (1.00) | PDE10APDE2ASLC28A2PDE5APDE6A | |
| SCHEMBL10098664 | 0.76 | PDE10A (0.85) | PDE10APDE2ASLC28A2PDE5APDE6A | |
| SCHEMBL7888724 | 0.75 | PDE10A (0.81) | PDE10APDE2ASLC28A2PDE5APDE6A | |
| SCHEMBL416240 | 0.73 | PDE10A (0.86) | PDE10APDE2ASLC28A2PDE5APDE6A | |
| SCHEMBL464195 | 0.73 | PDE10A (0.72) | PDE10APDE2ASLC28A2PDE5APDE6A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4284381-A1 | METHODS FOR THE TREATMENT OF CHILDHOOD-ONSET FLUENCY DISORDER | Noema Pharma AG (CH) | 2023-12-06 | — | — | EP | claimed |
| CN-117157077-A | Methods of treating childhood onset fluency disorders | 诺埃玛制药公司 | 2023-12-01 | — | — | CN | claimed |
| US-20230381193-A1 | METHODS FOR THE TREATMENT OF CHILDHOOD-ONSET FLUENCY DISORDER | NOEMA PHARMA AG (CH) | 2023-11-30 | — | — | US | claimed |
| WO-2022162193-A1 | METHODS FOR THE TREATMENT OF CHILDHOOD-ONSET FLUENCY DISORDER | NOEMA PHARMA AG (CH) | 2022-08-04 | — | — | WO | claimed |
| US-8492392-B2 | Alkoxy tetrahydro-pyridopyrimidine PDE10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-07-23 | — | — | US | claimed |
| WO-2010138430-A1 | ALKOXY TETRAHYDRO-PYRIDOPYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-12-02 | — | — | WO | claimed |
| US-20250304585-A1 | SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (COLDR) COMPOUNDS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2025-10-02 | — | — | US | disclosed |
| EP-4540249-A1 | SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (COLDR) COMPOUNDS | Yeda Research and Development Co. Ltd (IL) | 2025-04-23 | — | — | EP | disclosed |
| US-12178920-B2 | Nanocrystals, compositions, and methods that aid particle transport in mucus | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-12-31 | — | — | US | disclosed |
| US-20240139326-A1 | METHACRYLAMIDES PROTEIN BINDERS AND USES THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-05-02 | — | — | US | disclosed |
| US-20240115508-A1 | NANOCRYSTALS, COMPOSITIONS, AND METHODS THAT AID PARTICLE TRANSPORT IN MUCUS | THE JOHNS HOPKINS UNIVERSITY | 2024-04-11 | — | — | US | disclosed |
| US-11872318-B2 | Nanocrystals, compositions, and methods that aid particle transport in mucus | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-01-16 | — | — | US | disclosed |
| WO-2023242845-A1 | SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (CoLDR) COMPOUNDS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-12-21 | — | — | WO | disclosed |
| EP-2434885-B1 | ALKOXY TETRAHYDRO-PYRIDOPYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME (US) | 2014-03-26 | — | — | EP | disclosed |
| US-8492392-B2 | Alkoxy tetrahydro-pyridopyrimidine PDE10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492392-B2 | Alkoxy tetrahydro-pyridopyrimidine PDE10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-07-23 | — | — | US | disclosed |
| US-20120065211-A1 | ALKOXY TETRAHYDRO-PYRIDOPYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-03-15 | — | — | US | disclosed |
| US-20120065211-A1 | ALKOXY TETRAHYDRO-PYRIDOPYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-03-15 | — | — | US | disclosed |
| US-20120065211-A1 | ALKOXY TETRAHYDRO-PYRIDOPYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-03-15 | — | — | US | disclosed |
| WO-2010138430-A1 | ALKOXY TETRAHYDRO-PYRIDOPYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11872318-B2 | Nanocrystals, compositions, and methods that aid particle transport in mucus | MUC1, SLC35A1, EPCAM | PDE10A 477/4885PDE2A 410/4885SLC28A2 356/4885 |
| US-20240139326-A1 | METHACRYLAMIDES PROTEIN BINDERS AND USES THEREOF | STAMBP, HSPBP1, ECPAS | PDE10A 2391/4885PDE2A 2339/4885SLC28A2 4269/4885 |
| US-20120065211-A1 | ALKOXY TETRAHYDRO-PYRIDOPYRIMIDINE PDE10 INHIBITORS | PDE12, PDE4A, PDE5A | PDE10A 6/4885PDE2A 9/4885SLC28A2 2161/4885 |
| US-12178920-B2 | Nanocrystals, compositions, and methods that aid particle transport in mucus | MUC1, SLC35A1, EPCAM | PDE10A 477/4885PDE2A 410/4885SLC28A2 356/4885 |
| US-20240115508-A1 | NANOCRYSTALS, COMPOSITIONS, AND METHODS THAT AID PARTICLE TRANSPORT IN MUCUS | MUC1, SLC35A1, EPCAM | PDE10A 477/4885PDE2A 410/4885SLC28A2 356/4885 |
| US-20230381193-A1 | METHODS FOR THE TREATMENT OF CHILDHOOD-ONSET FLUENCY DISORDER | PDE10A, PDE4A, PDE7B | PDE10A 1/4885PDE2A 4/4885SLC28A2 2097/4885 |
| US-20250304585-A1 | SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (COLDR) COMPOUNDS | CASR, NPSR1, GSR | PDE10A 3041/4885PDE2A 4242/4885SLC28A2 1249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.